Restless Legs Syndrome :: Boehringer Ingelheim?s pramipexole for the treatment of Restless Legs Syndrome RLS
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the treatment of moderate to severe primary Restless Legs Syndrome (RLS).1 This is an important milestone for pramipexole (Mirapexin? / Sifrol? / Mirapex?), which was already approved throughout the European Union in April 2006 for this second indication.